Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation

I Johansson, M Oscarson, QY Yue, L Bertilsson, F Sjoqvist and M Ingelman-Sundberg

Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.

Cytochrome P4502D6 (CYP2D6) catalyzes the oxidative metabolism of several clinically important classes of drugs. Many of these have lower metabolic clearance rates among Chinese, compared with Caucasians, and are prescribed at lower doses for Asian patients. We have now evaluated the molecular genetic basis for this interethnic difference in drug metabolism. The CYP2D loci from two Chinese subjects, one homozygous for the XbaI 44-kilobase haplotype and one homozygous for the XbaI 29- kilobase haplotype, were cloned and characterized. Sequence analysis revealed two variant CYP2D6 genes, CYP2D6Ch1 and CYP2D6Ch2, having mutations yielding two and eight amino acid substitutions, respectively. Exon 9 of the CYP2D6Ch2 gene contained a sequence of 49 bases originating from the pseudogene CYP2D7P. In addition, mutations in the 5' flanking region common to both CYP2D6Ch genes were found. To evaluate the origin of the detrimental mutation in the genes, parts of the 5' flanking regions were introduced into a Hep G2/simian virus 40 expression system with chloramphenicol acetyltransferase as a reporter gene, and transfected cells were analyzed for activity. The ability of the upstream regions to bind nuclear factors was also evaluated using gel-shift analysis. Furthermore, several chimeric constructs of the CYP2D6wt and CYP2D6Ch genes were made, inserted into pCMV2 vectors, and expressed in COS-1 cells. A part of the upstream region of base pairs - 1407 to -1068 was found to constitute an enhancer element, but the CYP2D6Ch-specific mutations did not influence the chloramphenicol acetyltransferase activity in the expression system. In contrast, expression of the chimeric genes revealed that the detrimental mutation of the CYP2D6Ch genes was C188-->T, causing a Pro34-->Ser amino acid substitution in a region that is a highly conserved in cytochromes P450 belonging to gene families 1 and 2. This substitution caused expression of a more unstable gene product, as evident from comparison of the relative levels of CYP2D6 mRNA, CYP2D6 protein, and bufuralol 1'- hydroxylase activities in pCMV2-CYP2D6-transfected COS-1 cells. Allele- specific polymerase chain reaction analysis of genomic DNA from 90 Chinese individuals revealed that the CYP2D6Ch1 allele was the most common one and its distribution correlated well with a higher metabolic ratio for debrisoquine. These data demonstrate that important interethnic differences exist in the structure of the CYP2D locus, and they suggest that the frequent distribution of the C188-->T mutation among the CYP2D6Ch genes explains the lower capacity among Chinese to metabolize drugs that are substrates of CYP2D6, such as antidepressants and neuroleptic agents.

Volume 46, Issue 3, pp. 452-459, 09/01/1994
Copyright © 1994 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				Y. Xu, Y. Sun, L. Yao, L. Shi, Y. Wu, T. Ouyang, J. Li, T. Wang, Z. Fan, T. Fan, et al. Association between CYP2D6 *10 genotype and survival of breast cancer patients receiving tamoxifen treatment Ann. Onc., August 1, 2008; 19(8): 1423 - 1429. [Abstract] [Full Text] [PDF]

				R. E. Greene and V. Tsang Hormonal Therapy for the Treatment of Postmenopausal Breast Cancer Patients Journal of Pharmacy Practice, February 1, 2008; 21(1): 36 - 45. [Abstract] [PDF]

				H.-S. Lim, H. Ju Lee, K. Seok Lee, E. Sook Lee, I.-J. Jang, and J. Ro Clinical Implications of CYP2D6 Genotypes Predictive of Tamoxifen Pharmacokinetics in Metastatic Breast Cancer J. Clin. Oncol., September 1, 2007; 25(25): 3837 - 3845. [Abstract] [Full Text] [PDF]

				E. Eliasson Ethnicity and adverse drug reactions. BMJ, May 20, 2006; 332(7551): 1163 - 1164. [Full Text] [PDF]

				M. Sosa-Macias, G. Elizondo, C. Flores-Perez, J. Flores-Perez, F. Bradley-Alvarez, R. E. Alanis-Banuelos, and I. Lares-Asseff CYP2D6 Genotype and Phenotype in Amerindians of Tepehuano Origin and Mestizos of Durango, Mexico. J. Clin. Pharmacol., May 1, 2006; 46(5): 527 - 536. [Abstract] [Full Text] [PDF]

				A. Gaedigk, L. D. Bradford, S. W. Alander, and J. S. Leeder CYP2D6*36 GENE ARRANGEMENTS WITHIN THE CYP2D6 LOCUS: ASSOCIATION OF CYP2D6*36 WITH POOR METABOLIZER STATUS Drug Metab. Dispos., April 1, 2006; 34(4): 563 - 569. [Abstract] [Full Text] [PDF]

				S. Bernard, K. A. Neville, A. T. Nguyen, and D. A. Flockhart Interethnic Differences in Genetic Polymorphisms of CYP2D6 in the U.S. Population: Clinical Implications. Oncologist, February 1, 2006; 11(2): 126 - 135. [Abstract] [Full Text] [PDF]

				Y. Saito, N. Hanioka, K. Maekawa, T. Isobe, Y. Tsuneto, R. Nakamura, A. Soyama, S. Ozawa, T. Tanaka-Kagawa, H. Jinno, et al. FUNCTIONAL ANALYSIS OF THREE CYP1A2 VARIANTS FOUND IN A JAPANESE POPULATION Drug Metab. Dispos., December 1, 2005; 33(12): 1905 - 1910. [Abstract] [Full Text] [PDF]

				O. Q. P. Yin, X. J. Shi, B. Tomlinson, and M. S. S. Chow EFFECT OF CYP2D6*10 ALLELE ON THE PHARMACOKINETICS OF LORATADINE IN CHINESE SUBJECTS Drug Metab. Dispos., September 1, 2005; 33(9): 1283 - 1287. [Abstract] [Full Text] [PDF]

				K. Kim, J. A. Johnson, and H. Derendorf Differences in Drug Pharmacokinetics Between East Asians and Caucasians and the Role of Genetic Polymorphisms J. Clin. Pharmacol., October 1, 2004; 44(10): 1083 - 1105. [Abstract] [Full Text] [PDF]

				T. D. Bjornsson, J. A. Wagner, S. R. Donahue, D. Harper, A. Karim, M. S. Khouri, W. R. Murphy, K. Roman, D. Schneck, D. S. Sonnichsen, et al. A Review and Assessment of Potential Sources of Ethnic Differences in Drug Responsiveness J. Clin. Pharmacol., September 1, 2003; 43(9): 943 - 967. [Abstract] [Full Text] [PDF]

				H. Jinno, T. Tanaka-Kagawa, A. Ohno, Y. Makino, E. Matsushima, N. Hanioka, and M. Ando Functional Characterization of Cytochrome P450 2B6 Allelic Variants Drug Metab. Dispos., April 1, 2003; 31(4): 398 - 403. [Abstract] [Full Text] [PDF]

				N. Yasui-Furukori, K. Mihara, T. Kondo, T. Kubota, T. Iga, Y. Takarada, R. De Vries, S. Kaneko, and T. Tateishi Effects of CYP2D6 Genotypes on Plasma Concentrations of Risperidone and Enantiomers of 9-Hydroxyrisperidone in Japanese Patients with Schizophrenia J. Clin. Pharmacol., February 1, 2003; 43(2): 122 - 127. [Abstract] [Full Text] [PDF]

				A. Yu, B. M. Kneller, A. E. Rettie, and R. L. Haining Expression, Purification, Biochemical Characterization, and Comparative Function of Human Cytochrome P450 2D6.1, 2D6.2, 2D6.10, and 2D6.17 Allelic Isoforms J. Pharmacol. Exp. Ther., December 1, 2002; 303(3): 1291 - 1300. [Abstract] [Full Text] [PDF]

				T. Shiraishi, M. Hosokawa, K. Kobayashi, H. Tainaka, Y. Yamaura, M. Taguchi, and K. Chiba Effects of G169R and P34S Substitutions Produced by Mutations of CYP2D6*14 on the Functional Properties of CYP2D6 Expressed in V79 Cells Drug Metab. Dispos., November 1, 2002; 30(11): 1201 - 1205. [Abstract] [Full Text] [PDF]

				L. Ji, S. Pan, J. Marti-Jaun, E. Hanseler, K. Rentsch, and M. Hersberger Single-Step Assays to Analyze CYP2D6 Gene Polymorphisms in Asians: Allele Frequencies and a Novel *14B Allele in Mainland Chinese Clin. Chem., July 1, 2002; 48(7): 983 - 988. [Abstract] [Full Text] [PDF]

				Q. Mei, C. Tang, Y. Lin, T. H. Rushmore, and M. Shou Inhibition Kinetics of Monoclonal Antibodies against Cytochromes P450 Drug Metab. Dispos., June 1, 2002; 30(6): 701 - 708. [Abstract] [Full Text] [PDF]

				M. Garcia-Barcelo, L. Y. Chow, K. L. Lam, H. F. K. Chiu, Y. K. Wing, and M. M. Y. Waye Occurrence of CYP2D6 Gene Duplication in Hong Kong Chinese Clin. Chem., September 1, 2000; 46(9): 1411 - 1413. [Full Text] [PDF]

				E. M. SELLERS and R. F. TYNDALE Mimicking Gene Defects to Treat Drug Dependence Ann. N.Y. Acad. Sci., January 1, 2000; 909(1): 233 - 246. [Abstract] [Full Text] [PDF]

				M. Garcia-Barcelo, L. Y. Chow, H. F. K. Chiu, Y. K. Wing, D. T. S. Lee, K. L. Lam, and M. M. Y. Waye Genetic Analysis of the CYP2D6 Locus in a Hong Kong Chinese Population Clin. Chem., January 1, 2000; 46(1): 18 - 23. [Abstract] [Full Text] [PDF]

				S.-L. Wang, M.-D. Lai, and J.-d. Huang G169R Mutation Diminishes the Metabolic Activity of CYP2D6 in Chinese Drug Metab. Dispos., March 1, 1999; 27(3): 385 - 388. [Abstract] [Full Text]

				M. Oscarson, M. Hidestrand, I. Johansson, and M. Ingelman-Sundberg A Combination of Mutations in the CYP2D6*17 (CYP2D6Z) Allele Causes Alterations in Enzyme Function Mol. Pharmacol., December 1, 1997; 52(6): 1034 - 1040. [Abstract] [Full Text]

				Y. Hu, M. Oscarson, I. Johansson, Q.-Y. Yue, M.-L. Dahl, M. Tabone, S. Arinco, E. Albano, and M. Ingelman-Sundberg Genetic Polymorphism of Human CYP2E1: Characterization of Two Variant Alleles Mol. Pharmacol., March 1, 1997; 51(3): 370 - 376. [Abstract] [Full Text] [PDF]

				K. O. Lindros, T. Oinonen, I. Johansson, and M. Ingelman-Sundberg Selective Centrilobular Expression of the Aryl Hydrocarbon Receptor in Rat Liver J. Pharmacol. Exp. Ther., January 1, 1997; 280(1): 506 - 511. [Abstract] [Full Text]

				H. Kawashima, D. J. Sequeira, D. R. Nelson, and H. W. Strobel Genomic Cloning and Protein Expression of a Novel Rat Brain Cytochrome P-450 CYP2D18* Catalyzing Imipramine N-Demethylation J. Biol. Chem., November 8, 1996; 271(45): 28176 - 28180. [Abstract] [Full Text] [PDF]